<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0"><channel><title>Biopharma News Feed</title><link>https://nrouizem.github.io/test/custom_feed.xml</link><description>Daily curated &amp; AI-summarized biopharma news.</description><atom:link href="https://nrouizem.github.io/test/custom_feed.xml" rel="self"/><docs>http://www.rssboard.org/rss-specification</docs><generator>python-feedgen</generator><language>en</language><lastBuildDate>Fri, 07 Mar 2025 02:55:49 +0000</lastBuildDate><item><title>Transforming Early Detection in Oncology and Rare Diseases Using AI</title><link>https://www.fiercebiotech.com/premium/webinar/1368565</link><description>AI is transforming early detection in oncology and rare diseases by unlocking insights from unstructured healthcare data, improving diagnoses, and reducing costs amid growing resource constraints. Join experts Chris Tackaberry and Dr. Will Ricketts in a webinar exploring real-world AI successes, clinical NLP/ML applications, and strategies to enhance care through case studies from ASCO and Nature.</description><pubDate>Mon, 24 Feb 2025 14:53:21 +0000</pubDate></item><item><title>The Oncology Market: 2025 Outlook</title><link>https://www.fiercebiotech.com/resource/oncology-market-2025-outlook</link><description>&lt;span class="field field--name-title field--type-string field--label-hidden"&gt;The Oncology Market: 2025 Outlook&lt;/span&gt;

            &lt;div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__ite...</description><pubDate>Tue, 25 Feb 2025 14:49:58 +0000</pubDate></item><item><title>Redefining vaccine trial recruitment</title><link>https://www.fiercebiotech.com/resource/redefining-vaccine-trial-recruitment</link><description>Discover how innovative, data-driven strategies are tackling clinical trial recruitment challenges to ensure diverse, efficient, and high-quality vaccine development in Avacare's latest white paper. Sponsored by Avacare Clinical Research Network, this resource offers actionable insights for revolutionizing trial cohorts and enhancing vaccine research outcomes.</description><pubDate>Wed, 26 Feb 2025 14:26:35 +0000</pubDate></item><item><title>First Head-to-Head Study Cements Roche’s Xolair as Food Allergy Leader</title><link>https://www.biospace.com/drug-development/first-head-to-head-study-cements-roches-xolair-as-food-allergy-leader</link><description>Roche’s asthma drug Xolair has shown superior safety and effectiveness compared to oral immunotherapy in treating adults and children with multiple food allergies, according to a new study. The findings suggest Xolair could offer a more reliable option for reducing allergic reactions while posing fewer risks than current treatments.</description><pubDate>Mon, 03 Mar 2025 13:19:31 +0000</pubDate></item><item><title>Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial</title><link>https://www.biospace.com/drug-development/takeda-protagonist-drug-for-incurable-cancer-reduces-need-for-blood-withdrawals-in-phase-iii-trial</link><description>Protagonist Therapeutics hits a key milestone in its Takeda-partnered drug collaboration, as new trial data reveals rusfertide effectively reduced dangerously high hematocrit levels in chronic blood cancer patients without requiring phlebotomy. The findings suggest the therapy could offer a less invasive treatment path for managing the condition, marking a promising advance in hematologic care.</description><pubDate>Mon, 03 Mar 2025 15:38:54 +0000</pubDate></item><item><title>BeiGene Gets Yet Another Label Expansion for PD-1 Drug Tevimbra</title><link>https://www.biospace.com/fda/beigene-gets-yet-another-label-expansion-for-pd-1-drug-tevimbra</link><description>BeiGene's cancer therapy has been approved as a first-line treatment for esophageal squamous cell carcinoma, following a recent expansion of its use in gastric and gastroesophageal cancers. The company is also advancing a robust pipeline of novel oncology treatments to further strengthen its position in cancer care.</description><pubDate>Tue, 04 Mar 2025 14:59:25 +0000</pubDate></item><item><title>Using Client Centricity as Fuel for Innovative Biologics Development and Manufacturing Solutions</title><link>https://www.fiercebiotech.com/resource/using-client-centricity-fuel-innovative-biologics-development-and-manufacturing-solutions</link><description>A new whitepaper by Rentschler Biopharma offers biopharmaceutical professionals actionable insights for optimizing biologics development and manufacturing through a client-centric approach that maintains rigorous quality standards. Tailored for process and analytical scientists, manufacturing leaders, and executives, it highlights innovative strategies to streamline production while advancing cutting-edge biologics solutions.</description><pubDate>Tue, 04 Mar 2025 16:39:29 +0000</pubDate></item><item><title>Trump administration policies could create headwinds across healthcare: Fitch</title><link>https://www.biopharmadive.com/news/trump-administration-policies-create-headwinds-healthcare-fitch-ratings/741615/</link><description>Fitch Ratings warns that the current administration's regulatory initiatives may significantly lower credit ratings for major drugmakers and other corporations, citing heightened financial risks. The agency emphasizes that these policies could destabilize corporate finances across multiple sectors if left unchanged.</description><pubDate>Tue, 04 Mar 2025 21:00:00 +0000</pubDate></item><item><title>Priority Review Vouchers: By the Numbers</title><link>https://www.biospace.com/business/priority-review-vouchers-by-the-numbers</link><description>2024 set a record as the busiest year for FDA priority review vouchers, with BioSpace reporting 80 vouchers awarded across three agency programs to date. Companies have already invested $513 million this year in securing these time-saving vouchers, signaling heightened competition to accelerate drug approvals.</description><pubDate>Wed, 05 Mar 2025 14:06:00 +0000</pubDate></item><item><title>Jazz expands in oncology with $935M deal for Chimerix</title><link>https://www.biopharmadive.com/news/jazz-chimerix-acquisition-cancer-drug-dordaviprone/741636/</link><description>Chimerix anticipates an imminent FDA decision on whether its experimental therapy for a form of aggressive brain cancer, glioma, will receive accelerated approval to address urgent patient needs. The potential greenlight could expedite access to the treatment while ongoing clinical trials continue to confirm its efficacy and safety.</description><pubDate>Wed, 05 Mar 2025 16:53:00 +0000</pubDate></item><item><title>Tris to ask for approval of dual-acting pain drug</title><link>https://www.biopharmadive.com/news/tris-pain-drug-data-fda-approval-filing-plans/741727/</link><description>A company's novel drug demonstrated promising results in two acute pain studies, positioning it as a potential game-changer with a unique mechanism compared to current treatments. The breakthrough data has bolstered confidence in the drug’s viability, paving the way for it to emerge as a fresh option for pain management if approved.</description><pubDate>Thu, 06 Mar 2025 14:30:00 +0000</pubDate></item><item><title>Amgen readies pivotal MariTide trials; Novo offers discounted Wegovy</title><link>https://www.biopharmadive.com/news/amgen-maritide-trials-duchenne-base-editing-wegovy-discount/741651/</link><description>Amgen's obesity drug candidate has advanced to Phase 3 trials, with details now listed on a federal clinical trials database, signaling a critical step toward potential approval. Meanwhile, the FDA greenlit human testing for a pioneering base-editing therapy targeting Duchenne muscular dystrophy, marking a first for this innovative genetic approach.</description><pubDate>Thu, 06 Mar 2025 15:06:00 +0000</pubDate></item><item><title>Federal judge extends block on Trump plan to limit NIH payouts</title><link>https://www.biopharmadive.com/news/biotech-nih-funding-indirect-costs-trump-preliminary-injunction/741733/</link><description>A federal judge has blocked the Biden administration's controversial policy to impose nationwide caps on indirect costs for NIH research grants, dealing a blow to efforts to limit expenses like facilities and administration tied to federal funding. The ruling preserves current funding structures, averting what researchers and universities argued would cripple critical biomedical innovation and disrupt partnerships with the pharmaceutical industry.</description><pubDate>Thu, 06 Mar 2025 16:16:00 +0000</pubDate></item><item><title>Makary, under review to run FDA, evades pressure to reinstate canceled vaccine meeting</title><link>https://www.biopharmadive.com/news/makary-senate-hearing-fda-vaccines-meeting/741765/</link><description>President Trump's FDA nominee pledged during a Senate hearing to reassess which scientific decisions, such as drug approvals or safety evaluations, should require input from external advisory committees. The move could reshape how the agency leverages expert recommendations in its regulatory processes.</description><pubDate>Thu, 06 Mar 2025 17:30:00 +0000</pubDate></item><item><title>Following FDA cuts, Trump nominee Makary vows ‘independent’ staff review</title><link>https://www.biopharmadive.com/news/makary-hearing-fda-staffing-review-layoffs/741807/</link><description>A Johns Hopkins surgeon emphasized the agency's rapid expansion, assuring that essential personnel will receive "all the resources they need to do their job well." The pledge aims to maintain operational excellence amid growing demands as the organization scales up its efforts.</description><pubDate>Thu, 06 Mar 2025 20:42:00 +0000</pubDate></item><item><title>Vertex’s new pain drug gets first coverage nod from major insurer</title><link>https://www.biopharmadive.com/news/vertex-journavx-optum-united-health-coverage-tier-3/741850/</link><description>Optum, a UnitedHealth Group subsidiary, has temporarily added the drug Journavx to some commercial insurance formularies while conducting an ongoing review to assess its broader coverage. The interim decision allows immediate patient access, but a final determination hinges on the outcome of the continued evaluation.</description><pubDate>Thu, 06 Mar 2025 22:59:00 +0000</pubDate></item></channel></rss>
